昆藥集團(600422.SH)擬100萬元收購昆中藥健康餘下10%股權
格隆匯10月20日丨昆藥集團(600422.SH)公佈,為了將公司及相關子公司現有的非藥品類大健康產品管線做為公司的新興戰略單元培育,需要形成一個由公司100%控股的一個大健康一級投資平台,保證知識產權、品牌等重要資產的完整性,整合現有“小”、“散”、“亂”的非藥品類大健康業務。雲南昆中藥健康產業有限公司經過4年多的發展,已具備以上投資平台的功能。現有少數股東也表示願意服從大局,配合公司完成整合。
公司全資子公司昆明中藥廠有限公司擬出資人民幣90萬元向自然人萬江波購買其所持有的昆中藥健康的9%股權;擬出資人民幣10萬元向自然人姜健購買其所持有的昆中藥健康的1%股權。本次交易完成後,昆中藥將持有昆中藥健康100%股權。
據悉,雲南昆中藥健康產業有限公司註冊資金500萬元人民幣,經營範圍健康信息諮詢;預包裝食品、散裝食品、化粧品、日用百貨、消毒用品、醫療器械、中藥材、中藥飲片、保健食品的銷售等。2019年1月至7月,累計實現營業收入723.5萬元、淨利潤82.5萬元(以上數據未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.